Suven Life SciencesQ3 FY17

Suven Life Sciences Q3 FY17 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹268.65Market Cap: ₹7.6K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 4

Margin

Category 3

Fundraise

N/A

Order

No

Capex

Yes

1 of 4 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 4
  • Core CRAMS business expected to grow by 10% to 15% annually, as mentioned by Venkat Jasti.
  • Specialty chemicals segment is mature with flat or marginal growth expected (±5%).
  • Repeat business orders estimated around Rs. 40-50 crore in the next fiscal years (FY18-FY19).
  • No significant top-line growth currently; future growth depends on molecules in the pipeline advancing to next stages.
  • Clinical trial progress, especially on SUVN-502, is crucial for unlocking potential out-licensing deals and revenue growth.
  • New CAPEX of Rs. 100 crore planned for CRAMS facility enhancement to support future business opportunities.
  • Expected EBITDA margins sustained at around 30%, supporting profitability growth.
  • Specialty chemical revenues likely to remain around Rs. 200 crore range, with minor year-on-year variances.

See what Suven Life Sciences management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • There is no mention of any current or future fundraising through debt or equity in the provided transcript.
  • The management did not indicate plans for raising capital via equity or debt during this period.
  • CAPEX plans totaling Rs.100 crore over 15 months are funded internally for facility upgrades rather than through external fundraising.
  • The focus appears to be on organic growth through clinical trial progress and CRAMS business expansion.
  • No guidance or discussion was provided regarding capital raising activities in the call.

See what Suven Life Sciences management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Suven Life Sciences plans a significant capital expenditure (CAPEX) of Rs.100 crore over a 15-month period starting FY17.
  • This investment is for the construction of an additional block and upgradation of facilities at the CRAMS business site in Pashamylaram.
  • The CAPEX includes both recurring/replacement CAPEX of Rs.15 crore to Rs.20 crore annually and the new CAPEX for expansion.
  • Initial FY17 CAPEX is expected to be around Rs.20 crore as part of regular CAPEX.
  • For FY18, the company initially considered Rs.50 crore for facility upgradation but expanded it to Rs.100 crore by adding a new block.
  • This investment aims to enhance containment facilities and handle new chemical entities, supporting future growth in CRAMS.
  • No other specific strategic investments or out-licensing deals currently announced; focus remains on facility upgrades and clinical trial progression.

Track Suven Life Sciences — get its next earnings analysis in your feed

How does Suven Life Sciences rank vs peers in Healthcare Services?

Pro feature
ThisSuven Life Sciences
Rev 4Mar 3

How does Suven Life Sciences rank in Healthcare Services?

Compare Suven Life Sciences against every Healthcare Services company (Q3 FY17) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

Others in Healthcare Services this season

  • Chandan Healthca (Q2 FY27)

    Q2 FY27 operating income: ₹57.94 Cr, up 45.04% YoY from ₹39.95 Cr (Page 8) . Key investor presentation takeaways from Chandan Healthcare Ltd's Q2 FY27 investor

  • Invicta Diagnostic (Q2 FY27)

    Revenue from operations for the half year ended September 30, 2026: ₹379.11 lakhs (Page 4). Key results statement takeaways from Invicta Diagnostic Ltd's Q2 FY2

  • Unihealth Hosp (Q2 FY27)

    1,270 million with a year-on-year (YoY) growth of 6.3% . Key results statement takeaways from Unihealth Hospitals Ltd's Q2 FY27 results statement — and how it r

  • Sangani Hospital (Q2 FY27)

    1008.56 lakhs (~11.8% increase). Key results statement takeaways from Sangani Hospitals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →